Y-Intercept (HK)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Y-Intercept (HK)’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.01M	Sell	62,211 -58,613	-49%	-$935K	0.02%	1015
2026 Q2	$2.05M	Buy	120,824 +49,366	+69%	+$789K	0.04%	689
2026 Q1	$1.06M	Buy	+71,458	New	+$1.04M	0.02%	1011
2025 Q2	–	Sell	-17,410	Closed	-$140K	–	1624
2025 Q1	$140K	Buy	+17,410	New	+$141K	0.01%	1090
2023 Q2	–	Sell	-10,586	Closed	-$116K	–	1258
2023 Q1	$116K	Sell	10,586 -6,210	-37%	-$54.7K	0.01%	1039
2022 Q4	$72.6K	Buy	+16,796	New	+$97.5K	0.01%	906

Other funds holding AUPH

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Capital Investment Advisors Atlanta, Georgia $7.74B AUM 15.52% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Kathmere Capital Management Wayne, Pennsylvania $2.07B AUM 20.3% 1-Year Est. Return

Acropolis Investment Management St. Louis, Missouri $2.49B AUM 10.8% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Y-Intercept (HK)'s AUPH Position: Q3 2026 in Review

Y-Intercept (HK) reduced its Aurinia Pharmaceuticals (AUPH) stake by 49% in Q3 2026, selling an estimated $935K and leaving 62,211 shares worth $1.01M. The position accounts for 0.02% of the portfolio, ranked #1015.

Y-Intercept (HK) first reported a position in AUPH in Q4 2022 and has held it in 6 quarters since. The position peaked at $2.05M in Q2 2026. 29 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

Y-Intercept (HK) held 62,211 shares of Aurinia Pharmaceuticals worth $1.01M as of Q3 2026.
Y-Intercept (HK) sold 58,613 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $935K.
Aurinia Pharmaceuticals made up 0.02% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1015 holding.
Y-Intercept (HK) first reported a position in Aurinia Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
Y-Intercept (HK)'s Aurinia Pharmaceuticals position peaked at $2.05M in Q2 2026.
29 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.